CA2721061C - Treatment of thromboangiitis obliterans by removal of autoantibodies - Google Patents
Treatment of thromboangiitis obliterans by removal of autoantibodies Download PDFInfo
- Publication number
- CA2721061C CA2721061C CA2721061A CA2721061A CA2721061C CA 2721061 C CA2721061 C CA 2721061C CA 2721061 A CA2721061 A CA 2721061A CA 2721061 A CA2721061 A CA 2721061A CA 2721061 C CA2721061 C CA 2721061C
- Authority
- CA
- Canada
- Prior art keywords
- patient
- specific ligand
- plasma
- treatment
- column
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 44
- 206010043540 Thromboangiitis obliterans Diseases 0.000 title claims abstract description 33
- 208000033386 Buerger disease Diseases 0.000 title claims abstract description 30
- 239000003446 ligand Substances 0.000 claims abstract description 35
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 108060003951 Immunoglobulin Proteins 0.000 claims description 28
- 102000018358 immunoglobulin Human genes 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 23
- 210000003462 vein Anatomy 0.000 claims description 17
- 210000001367 artery Anatomy 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 101710120037 Toxin CcdB Proteins 0.000 claims description 4
- 101100257994 Arabidopsis thaliana FAB2 gene Proteins 0.000 claims description 3
- 102100038028 1-phosphatidylinositol 3-phosphate 5-kinase Human genes 0.000 claims 2
- 101001025044 Homo sapiens 1-phosphatidylinositol 3-phosphate 5-kinase Proteins 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 201000010099 disease Diseases 0.000 description 18
- 210000002683 foot Anatomy 0.000 description 16
- 238000002560 therapeutic procedure Methods 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 208000007536 Thrombosis Diseases 0.000 description 10
- 210000003414 extremity Anatomy 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 206010047115 Vasculitis Diseases 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 238000002266 amputation Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 4
- 208000031229 Cardiomyopathies Diseases 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 208000001297 phlebitis Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 3
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 3
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 3
- 208000009433 Moyamoya Disease Diseases 0.000 description 3
- 241000208125 Nicotiana Species 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- 201000007527 Retinal artery occlusion Diseases 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 206010043189 Telangiectasia Diseases 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 206010003230 arteritis Diseases 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 229940127240 opiate Drugs 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 230000008844 regulatory mechanism Effects 0.000 description 3
- 208000004644 retinal vein occlusion Diseases 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000009056 telangiectasis Diseases 0.000 description 3
- 230000001732 thrombotic effect Effects 0.000 description 3
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010002921 Aortitis Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000027496 Behcet disease Diseases 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- 206010009895 Colitis ischaemic Diseases 0.000 description 2
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 2
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 2
- 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000013038 Hypocalcemia Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 208000031814 IgA Vasculitis Diseases 0.000 description 2
- 208000011200 Kawasaki disease Diseases 0.000 description 2
- 208000002364 Leriche syndrome Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 2
- 208000004531 Renal Artery Obstruction Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000001106 Takayasu Arteritis Diseases 0.000 description 2
- 208000000558 Varicose Ulcer Diseases 0.000 description 2
- 206010046996 Varicose vein Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 201000002331 allergic cutaneous vasculitis Diseases 0.000 description 2
- 208000000252 angiomatosis Diseases 0.000 description 2
- 201000005265 anterior compartment syndrome Diseases 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 208000006170 carotid stenosis Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 206010010121 compartment syndrome Diseases 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 208000002528 coronary thrombosis Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000009101 diabetic angiopathy Diseases 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000011384 erythromelalgia Diseases 0.000 description 2
- 208000008487 fibromuscular dysplasia Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 201000006362 hypersensitivity vasculitis Diseases 0.000 description 2
- 230000000705 hypocalcaemia Effects 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 201000008222 ischemic colitis Diseases 0.000 description 2
- 201000002818 limb ischemia Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000008287 mesenteric vascular occlusion Diseases 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 description 2
- 201000008312 primary pulmonary hypertension Diseases 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 201000004822 varicocele Diseases 0.000 description 2
- 208000027185 varicose disease Diseases 0.000 description 2
- 201000002282 venous insufficiency Diseases 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 206010002412 Angiocentric lymphomas Diseases 0.000 description 1
- 208000004375 Angiodysplasia Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000007257 Budd-Chiari syndrome Diseases 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000009447 Cardiac Edema Diseases 0.000 description 1
- 208000006017 Cardiac Tamponade Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000014882 Carotid artery disease Diseases 0.000 description 1
- 206010007688 Carotid artery thrombosis Diseases 0.000 description 1
- 208000021910 Cerebral Arterial disease Diseases 0.000 description 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000000425 Chagas Cardiomyopathy Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 1
- 206010019713 Hepatic vein thrombosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 201000008450 Intracranial aneurysm Diseases 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 208000009378 Low Cardiac Output Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 208000025047 Non-histaminic angioedema Diseases 0.000 description 1
- 208000026251 Opioid-Related disease Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 206010048731 Pneumopericardium Diseases 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 208000014777 Pulmonary venoocclusive disease Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 description 1
- 208000000924 Right ventricular hypertrophy Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 206010042265 Sturge-Weber Syndrome Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 206010043647 Thrombotic Stroke Diseases 0.000 description 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000003608 autoimmunological effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000005761 carcinoid heart disease Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000035601 cold sensitivity Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 208000006331 coronary aneurysm Diseases 0.000 description 1
- 201000011634 coronary artery vasospasm Diseases 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 206010014663 endocardial fibroelastosis Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000018645 hepatic veno-occlusive disease Diseases 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 201000007272 intracranial sinus thrombosis Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000002089 myocardial stunning Diseases 0.000 description 1
- 208000013435 necrotic lesion Diseases 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 201000005040 opiate dependence Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000013186 photoplethysmography Methods 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000010577 post-coronary angioplasty Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 208000009169 relapsing polychondritis Diseases 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 206010051951 scimitar syndrome Diseases 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 235000019505 tobacco product Nutrition 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/49—Method of mechanical manufacture
- Y10T29/49826—Assembling or joining
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08075309A EP2110140A1 (en) | 2008-04-18 | 2008-04-18 | Treatment of thromboangiitis obliterans by removal of autoantibodies |
| EP08075309.8 | 2008-04-18 | ||
| PCT/EP2009/002993 WO2009143944A2 (en) | 2008-04-18 | 2009-04-20 | Treatment of thromboangiitis obliterans by removal of autoantibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2721061A1 CA2721061A1 (en) | 2009-12-03 |
| CA2721061C true CA2721061C (en) | 2016-06-28 |
Family
ID=39683905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2721061A Expired - Fee Related CA2721061C (en) | 2008-04-18 | 2009-04-20 | Treatment of thromboangiitis obliterans by removal of autoantibodies |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8663147B2 (enExample) |
| EP (2) | EP2110140A1 (enExample) |
| JP (1) | JP5718807B2 (enExample) |
| CN (1) | CN102006888A (enExample) |
| CA (1) | CA2721061C (enExample) |
| ES (1) | ES2560456T3 (enExample) |
| WO (1) | WO2009143944A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11008365B2 (en) | 2016-09-01 | 2021-05-18 | National Institute Of Advanced Industrial Science And Technology | Polypeptide exhibiting affinity to antibodies forming non-native three-dimensional structure |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1409245A1 (ru) | 1985-04-12 | 1988-07-15 | Научно-исследовательский институт травматологии и ортопедии | Способ лечени врожденного вывиха бедра |
| SU1409275A1 (ru) * | 1985-06-10 | 1988-07-15 | Томский Медицинский Институт | Способ лечени псориаза |
| ATE266415T1 (de) * | 1995-11-15 | 2004-05-15 | Edwards Lifesciences Corp | Behandlung von dilatierte kardiomyopathie durch entfernung von autoantikoerpern |
| RU2153168C2 (ru) | 1997-11-25 | 2000-07-20 | Научно-исследовательский институт кардиологии | Способ определения показаний к проведению плазмафереза при лечении стенокардии |
| US6551266B1 (en) | 1998-12-29 | 2003-04-22 | Occulogix Corporation | Rheological treatment methods and related apheresis systems |
| EP2228389B1 (en) * | 2001-04-13 | 2015-07-08 | Human Genome Sciences, Inc. | Antibodies against vascular endothelial growth factor 2 |
| DE102006003782A1 (de) | 2006-01-25 | 2007-08-02 | Protagen Ag | Immunadsorptionstherapie mittels Autoantigenen |
| US20100047211A1 (en) * | 2006-05-19 | 2010-02-25 | The Johns Hopkins University | Method of growth of mesenchymal cells under non-adherent conditions for clinical applications |
| US8088600B2 (en) * | 2006-10-18 | 2012-01-03 | Centocor Ortho Biotech Inc. | Nucleic acids encoding cynomolgus IL-13 mutein proteins |
| WO2008151847A1 (en) | 2007-06-13 | 2008-12-18 | Max-Delbrück-Centrum für Molekulare Medizin | Autoantibody binding peptides and their use for the treatment of vascular diseases |
-
2008
- 2008-04-18 EP EP08075309A patent/EP2110140A1/en not_active Withdrawn
-
2009
- 2009-04-20 JP JP2011504387A patent/JP5718807B2/ja not_active Expired - Fee Related
- 2009-04-20 CA CA2721061A patent/CA2721061C/en not_active Expired - Fee Related
- 2009-04-20 EP EP09753599.1A patent/EP2288384B1/en not_active Not-in-force
- 2009-04-20 US US12/988,267 patent/US8663147B2/en not_active Expired - Fee Related
- 2009-04-20 CN CN2009801134903A patent/CN102006888A/zh active Pending
- 2009-04-20 ES ES09753599.1T patent/ES2560456T3/es active Active
- 2009-04-20 WO PCT/EP2009/002993 patent/WO2009143944A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011517690A (ja) | 2011-06-16 |
| ES2560456T3 (es) | 2016-02-19 |
| US8663147B2 (en) | 2014-03-04 |
| CN102006888A (zh) | 2011-04-06 |
| WO2009143944A2 (en) | 2009-12-03 |
| EP2288384A2 (en) | 2011-03-02 |
| EP2110140A1 (en) | 2009-10-21 |
| JP5718807B2 (ja) | 2015-05-13 |
| CA2721061A1 (en) | 2009-12-03 |
| WO2009143944A3 (en) | 2010-08-05 |
| US20110105980A1 (en) | 2011-05-05 |
| EP2288384B1 (en) | 2015-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0862444B1 (en) | Treatment of dilated cardiomyopathy by removal of autoantibodies | |
| Chaung et al. | Mitochondrial transcription factor A is a proinflammatory mediator in hemorrhagic shock | |
| CN1160126C (zh) | 败血症治疗用免疫吸附剂 | |
| BR112020005450A2 (pt) | aglutinante antiadrenomedulina (adm) para uso em terapia ou prevenção dos sintomas de doença | |
| JP2016216483A (ja) | 活性化増強型抗体の効果を増大させる方法 | |
| CA2721061C (en) | Treatment of thromboangiitis obliterans by removal of autoantibodies | |
| US4087519A (en) | Medicament for the treatment of hepatitis and/or acute or chronic infections due to the virus of hepatitis B | |
| Ohning et al. | Differential kinetics for immunoneutralization of circulating gastrin by gastrin monoclonal antibody and its Fab1 fragment in rats | |
| JP2001509517A (ja) | 微小循環障害の治療及び／又は予防のための薬剤 | |
| ES2423007T3 (es) | Uso de una matriz para la eliminación de proteína C reactiva de fluidos biológicos | |
| Ptak et al. | Immunoadsorption therapy and complement activation | |
| Kobzik et al. | Demonstration of an idiotypic antigen on a monoclonal cold agglutinin and on its isolated heavy and light chains. | |
| ES2433280T3 (es) | Adsorbente inmunológico para el tratamiento de inflamaciones | |
| CN109470852A (zh) | 一种母乳多克隆抗体免疫亲和柱及其制备方法 | |
| CA2236598C (en) | Treatment of cardiomyopathy by removal of autoantibodies | |
| RU2526153C2 (ru) | Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция | |
| RU2651005C2 (ru) | Способ повышения фармакологической активности активированной-потенцированной формы антител к простатоспецифическому антигену и фармацевтическая композиция | |
| RU2542403C2 (ru) | Способ коррекции эндотелиальной дисфункции | |
| FR2578425A1 (fr) | Preparations d'immunoglobulines presentant des titres eleves en anticorps bloquants anti-allergenes, leur preparation et leurs applications pour le traitement d'allergies | |
| RU2500424C2 (ru) | Лекарственное средство для коррекции эндотелиальной дисфункции | |
| Mauch et al. | A simple and efficient method for preparation of immunoelectrophoretically pure guinea pig IgM and isolation of monospecific anti-IgM antibodies | |
| dans la Region | Ulllted States Patent [19][11] Patent Number: 6,069,236 | |
| JPH08198900A (ja) | 毛髪特異抗体の精製方法 | |
| JPH0247447B2 (ja) | Kohotaikanohikuiigmsoseibutsu | |
| JPH01238541A (ja) | 抗血清の製造法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20200831 |